Clinical Pharmacokinetics of Pravastatin

Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1993 • 28,274 citations

The Lipid Research Clinics Coronary Primary Prevention Trial Results

1984 • 2,673 citations

Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B

1990 • 2,192 citations

Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin

1986 • 1,857 citations

Beneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis and Coronary Venous Bypass Grafts

1987 • 1,651 citations

Lipid Alterations and Decline in the Incidence of Coronary Heart Disease in the Helsinki Heart Study

1988 • 946 citations

ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogensis produced by Penicillium citrinum.

1976 • 926 citations

HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia

1988 • 760 citations

Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study.

1984 • 685 citations

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering

1984 • 631 citations

RISKS OF ISCHÆMIC HEART-DISEASE IN FAMILIAL HYPERLIPOPROTEINÆMIC STATES

1969 • 623 citations

The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association.

1990 • 568 citations

The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study.

1984 • 449 citations

Discovery, biochemistry and biology of lovastatin

1988 • 348 citations

Efficacy and long-term adverse effect pattern of lovastatin

1988 • 338 citations

Drugs Affecting Lipid Metabolism

1993 • 216 citations

Clinical Pharmacokinetics and Practical Applications of Simvastatin

1993 • 182 citations

Disposition of pravastatin sodium, a tissue‐selective HMG‐CoA reductase inhibitor, in healthy subjects.

1990 • 174 citations

Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver

1993 • 154 citations

Comparative Pharmacokinetics and Pharmacodynamics of Pravastatin and Lovastatin

1990 • 149 citations

Heterozygous familial hypercholesterolemia

1979 • 128 citations

Concentrations of Pravastatin and Lovastatin in Cerebrospinal Fluid in Healthy Subjects

1991 • 126 citations

Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients.

1993 • 113 citations

Biotransformation of pravastatin sodium in humans.

1991 • 108 citations

Comparative Pharmacokinetics of Lovastatin, Simvastatin and Pravastatin in Humans

1992 • 103 citations

Efficacy and safety of pravastatin in patients with primary hypercholesterolemia

1990 • 87 citations

Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia

1990 • 82 citations

Clinical experience with lovastatin

1990 • 79 citations

The Effect of CS-514 on Serum Lipids and Apolipoproteins in Hypercholesterolemic Subjects

1987 • 79 citations

Efficacy and safety of pravastatin in patients with primary hypercholesterolemia

1990 • 77 citations

A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin.

1993 • 72 citations

Effects of lovastatin and pravastatin on sleep efficiency and sleep stages

1991 • 71 citations

Once‐daily pravastatin in patients with primary hypercholesterolemia: A dose‐response study

1991 • 66 citations

Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rat

1992 • 62 citations

Single‐Dose Pharmacokinetics of Pravastatin and Metabolites in Patients with Renal Impairment

1992 • 52 citations

Effect of food on pravastatin pharmacokinetics and pharmacodynamics.

1993 • 51 citations

The Effect of CS-514, an Inhibitor of HMG-CoA Reductase, on Serum Lipids in Healthy Volunteers

1986 • 49 citations

Determination of pravastatin sodium and its major metabolites in human serum/plasma by capillary gas chromatography/negative ion chemical ionization mass spectrometry

1989 • 47 citations

Pharmacokinetic interaction between propranolol and the HMG‐CoA reductase inhibitors pravastatin and lovastatin.

1991 • 43 citations

Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase.

1991 • 40 citations

Clinical Implications of New Drugs for Lowering Plasma Cholesterol Concentrations

1991 • 34 citations

Current approaches to drug therapy for the hypercholesterolemic patient.

1989 • 28 citations

Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia

1994 • 27 citations

Lovastatin and simvastatin prevention studies

1990 • 23 citations

Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II

1993 • 22 citations

Long-term experience with pravastatin in clinical research trials.

1993 • 20 citations

The Clinical Pharmacology of SQ 31,000 (CS 514) in Healthy Subjects

1987 • 16 citations

3-Hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors: A New Class of Cholesterol-Lowering Agents

1987 • 10 citations

Drug development report (6): Pravastatin: A hydrophilic inhibitor of cholesterol synthesis

1990 • 6 citations